Literature DB >> 7620336

Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma.

A Platz1, U Ringborg, E Grafström, A Höög, B Lagerlöf.   

Abstract

Immunohistochemical analysis of the N-ras p21 and the p53 proteins was carried out on formalin-fixed sections of naevi, primary melanomas and metastases from patients with sporadic melanoma (SCMM) and with hereditary melanoma (HCMM)/dysplastic naevus syndrome (DNS). Seven out of 11 (64%) common naevi and three out of nine (33%) dysplastic naevi showed increased cytoplasmic N-ras expression. No p53 immunopositivity could be recognized in any of the naevus samples. However, strong N-ras expression as well as immunopositivity for p53 was recognized among primary melanomas and metastases with significantly higher frequency among samples from patients with HCMM compared with samples from SCMM cases (for N-ras, 40% vs 10%, P < 0.01; and for p53 43% vs 17%, P < 0.05). We have earlier registered N-ras codon 61 mutations among metastases from 59% of patients with HCMM and from 24% of subjects with SCMM. A comparison of the genetic data with the immunohistochemical results showed occurrence of increased N-ras p21 expression in the presence and absence of detectable N-ras mutant alleles. Increased expression of wildtype N-ras p21 may contribute to tumorigenicity in the absence of mutational activation, at least in a subset of melanomas. Altogether, N-ras p21 alterations are registered at earlier stages than p53 alterations in melanoma development and may be of aetiological importance, whereas p53 alterations may be associated with tumour progression in the late stages.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620336     DOI: 10.1097/00008390-199504000-00005

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

Authors:  S Seregard
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

Review 3.  Activated ras. Yet another player in melanoma?

Authors:  M Herlyn; K Satyamoorthy
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

4.  Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.

Authors:  K Margolin; J Longmate; T W Synold; D R Gandara; J Weber; R Gonzalez; M J Johansen; R Newman; T Baratta; J H Doroshow
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 5.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Authors:  Anton Platz; Suzanne Egyhazi; Ulrik Ringborg; Johan Hansson
Journal:  Mol Oncol       Date:  2007-12-28       Impact factor: 6.603

7.  Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases.

Authors:  A Platz; P Sevigny; T Norberg; P Ring; B Lagerlöf; U Ringborg
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.